Major Shareholding Notification
Idag, 17:16
Major Shareholding Notification
Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.
Prior to the transaction, the shareholder held 5.29% of the share capital and voting rights in the Company. Following the transaction, the shareholder holds now 4.85%, corresponding to an ownership interest below 5%.
This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
Ämnen i artikeln
Major Shareholding Notification
Idag, 17:16
Major Shareholding Notification
Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.
Prior to the transaction, the shareholder held 5.29% of the share capital and voting rights in the Company. Following the transaction, the shareholder holds now 4.85%, corresponding to an ownership interest below 5%.
This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
Ämnen i artikeln
Novo Nordisk
Aktierekommendationer
Aktier
Analyser
Mest läst
Novo Nordisk
Aktierekommendationer
Aktier
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
